NMPA Approves World's First Plant-Based Human Albumin for Liver Cirrhosis Treatment
CompanyDrug

NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment

KANTE Biotech's Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection
CompanyMedical Device

KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings
Company

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings

Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment
CompanyDrug

Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment

CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards
Policy / Regulatory

CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards

Novo Nordisk's Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control
CompanyDrug

Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control

Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion
CompanyDeals

Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion

Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025
Policy / Regulatory

Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025

Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China's Digestive-Health Market
CompanyDeals

Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market

Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension
CompanyDrug

Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension

VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies
CompanyDeals

VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
CompanyDrug

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029